viewProvectus Pharmaceuticals

Provectus notes PV-10 research data release

It is researching PV-10 in melanoma, breast cancer and cancers of the liver

PV-10 is a treatment designed to be injected into solid tumours

Cancer and dermatology specialist Provectus Biopharmaceuticals (NYSE:PVCT) highlighted data has been released on the immunology effects of its PV-10 treatment in colon cancer cells.

PV-10 is a treatment designed to be injected into solid tumours, particularly in melanoma, breast cancer and cancers of the liver, lowering the risk of potential side effects.

The research note - PV-10 Induces Potent Immunogenic Apoptosis in Colon Cancer Cells – was presented at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.

The presentation, made by Dr Kunda from the University of Illinois, noted that in vitro testing of PV-10 on colon cancer showed it was toxic to the cancerous cells.

Dr Eric Wachter, chief technological officer of Provectus, said: “The work reported in Dr. Kunda’s presentation further expands our understanding of the mechanism of action of PV-10 as an ablative immunotherapy for solid tumors, and parallels immunologic signaling noted upon ablation of melanoma with PV-10.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of...

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California. Bunka telling Proactive...

1 day, 3 hours ago

2 min read